{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-016708","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.310442+00:00","generated_at":"2026-05-27T00:09:01.469177+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150","bullets":["Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.","Recently diagnosed subgroup (n=15): 94% reduction (0.33 mean injections); 80% injection-free.","Safety: well tolerated up to 3 years; 2.8% (2/71) 4D-150-related 1+ IOI; no hypotony, endophthalmitis, or vasculitis.","Durable aflibercept expression up to 2 years; aqueous humor levels consistently within projected therapeutic range.","Phase 3 trials 4FRONT-1 (Q1 2025) and 4FRONT-2 (Q3 2025) to initiate; topline 52-week data expected H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-016708","json":"https://secwatch.observer/filing/0000950170-25-016708.json","markdown":"https://secwatch.observer/filing/0000950170-25-016708.md","text":"https://secwatch.observer/filing/0000950170-25-016708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025016708/0000950170-25-016708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025016708/fdmt-20250208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:09:01.469177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}